echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > New antibiotics are effective against a wide range of bacteria

    New antibiotics are effective against a wide range of bacteria

    • Last Update: 2020-12-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    scientists at the Westa Institute in the United States have discovered a new class of compounds that directly kill drug-resistant pathogens while triggering a rapid immune response against antimicrobial resistance (AMR). The paper was published in Nature on December 24.
    World Health Organization has declared antibiotic resistance one of the world's top ten public health threats. It is estimated that antibiotic-resistant infections could kill 10 million people a year by 2050, burdening the global economy by a cumulative $100 trillion. The list of drug-resistant bacteria is growing, but few new drugs are in development, creating an urgent need for new antibiotics.
    "We creatively propose a two-pronged strategy to develop new molecules that can kill hard-to-treat bacteria while enhancing the host's natural immune response." Farokh Dotiwala, an assistant professor at the agency, said, "And attacking bacteria on two different fronts at the same time makes it difficult for bacteria to develop resistance." "The researchers named this new generation of antibiotics Immune-Antibacterial Dual Effects (DAIAs).
    basic functions of existing antibiotic-targeted bacteria, including nucleic acid and protein synthesis, cell membrane construction, and metabolic pathways. However, bacteria can gain resistance by changing the target of the antibiotic, inferging the drug or pumping it out.
    dotiwala and others have focused on a metabolic pathway that is critical to most bacteria but is missing in humans, making it an ideal target for antibiotic development. This pathway, known as the non-methyl hydroxypropypyl acid pathway, is responsible for the biosynthesis of isoprene compounds, the molecules necessary for the survival of most pathogenic bacterial cells. The lab targeted IspH enzyme, a isoprene biosynthetic enzyme, as a way to block this pathway and kill microorganisms. Given the widespread presence of IspH in the bacterial community, this approach may target a wide range of bacteria.
    used computer modeling techniques to screen millions of commercially available compounds that bind to IspH and chose the most effective compounds that inhibit IspH function as a starting point for drug development.
    the team demonstrated that IspH inhibitors stimulate the immune system to be more aggressive and specific than the best antibiotics of its kind in in-body testing of clinically isolated drug-resistant bacteria. In preclinical models of Glorene-negative bacterial infections, IspH inhibitors are more bactericidal than conventional antibiotics. All tested compounds have been shown to be non-toxic to human cells. (Source: Tang Feng, China Science Journal)
    related paper Information:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.